Neuberger Berman Group
AGRX

Neuberger Berman Group’s Agile Therapeutics AGRX Stock Holding History

Neuberger Berman Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-69
Closed -$613K – 1832
2017
Q3 		$613K Buy
+69
New +$530K ﹤0.01% 1257

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group's AGRX Position: Q4 2017 in Review

Neuberger Berman Group sold out of Agile Therapeutics (AGRX) in Q4 2017, closing a stake of 69 shares — an estimated $613K sold.

Neuberger Berman Group first reported a position in AGRX in Q3 2017 and held it in 1 quarter. The position peaked at $613K in Q3 2017. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2017.

  • Neuberger Berman Group reported no remaining Agile Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 69 Agile Therapeutics shares in Q4 2017, an estimated $613K.
  • Neuberger Berman Group first reported a position in Agile Therapeutics in Q3 2017 and held it in 1 quarter.
  • Neuberger Berman Group's Agile Therapeutics position peaked at $613K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2017.

Based on Neuberger Berman Group's 13F filing for Q4 2017, filed 14 Feb 2018.